Search

CAP-1

Aloe vera leaf

Acemannan and other modified polysaccharides are responsible in preventing suppression of contact hypersensitivity or immune suppression induced by external factors such as irradiation [A32473].

Arbutin

Arbutin is available in both natural and synthetic forms; it can be synthesized from acetobromglucose and [DB09526] [F43]. … It has also been used as an anti-infective for the urinary system as well as a diuretic [F43].

Nimodipine

Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. … It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation.

Cetirizine

The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. … Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal

Tetracycline

Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. … It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site.

Romiplostim

The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. … Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008.

Ginger

Ginger allergenic extract is used in allergenic testing.

Minocycline

Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifi...

Peginterferon beta-1a

Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.